Top of page Skip navigation



Edward Lumley Hall


Networking breakfast and partnering


Vandervell Lecture Theatre



Steve Bates
Chief Executive Officer, BIA


State of the nation update and presentation on report findings
Join a discussion on the top three reasons the UK is one of the best places for life science research and hear a snapshot of the latest UK industry trends

Ian Oliver
Executive Director, Audit and Advisory Business Services, EY

Dr Edward Hodgkin
Partner, Syncona Partners and Chairman, BIA

Andrew Jack
Pharmaceuticals Correspondent, Financial Times

10.00 – 10.20

Life Sciences in London - the importance of life sciences to London and the key role it will play in the coming years

Boris Johnson
Mayor of London

10.20 – 10.45

BBSRC Innovator of the Year

Dr Ryan Donnelly
Lecturer in Pharmaceuticals, School of Pharmacy, Queen’s University Belfast

Microneedles for transdermal drug delivery and patient monitoring

In this session delegates will hear from Dr Donnelly on his unique innovation of microneedle arrays.

This technology has the potential to overcome the limitations of conventional microneedle designs and greatly increase the range of type of drug deliverable transdermally, with ensuing benefits for industry, healthcare providers and, ultimately, patients. Importantly, such systems also have potential for use in minimally-invasive patient monitoring applications, through capture of skin interstitial fluid.


Edward Lumley Hall

10.45 -11.15

Refreshments, networking and partnering

11.15 - 12.45

 Council Room

Eleanor Davies-Colley Lecture Theatre

Vandervell Lecture Theatre


Biologics, vaccines and cells manufacturing - is there common ground?

An informative panel discussion covering the manufacturing challenges and how the Cell Therapy Catapult and the National Biologics Manufacturing Centre are being positioned to address them including

 - Technologies
 - Scale
 - Centralised vs localised manufacturing


Dr Stephen Ward
Chief Operating Officer, Cell Therapy Catapult and Chair, BIA Manufacturing Advisory Committee


Dr Gary Brooke
Project Manager for Cell Manufacturing, ReNeuron

Professor Chris Mason
Professor of Regenerative Medicine Bioprocessing, UCL

Dr Sarah Moyle
Head of Clinical BioManufacturing Facility, Oxford University

Dr David Venables
Chief Executive Officer, BioMelior Services



Intellectual Property Hot Topics

The Intellectual Property Advisory Committee brings you the latest Hot Topics in the IP arena. This session will give delegates the opportunity to hear from and discuss developments with key IP and legal experts.


John Murphy
General Counsel and Company Secretary, Skye Pharma and Chair, BIA Intellectual Property Advisory Committee


Unitary Patent – latest updates

Rebecca Baines
enior Associate, Rouse

Nicola Baker-Munton
Chief Executive Officer, Stratagem IPM

Supplementary Protection Certificate (SPCs)

Dr Tony Proctor
Associate, Potter Clarkson

Gene patenting in Europe and the US after Myriad

Morag Peberdy
Of Counsel, Covington & Burling

Tackling anti-microbial resistance and healthcare-associated infections

England’s Chief Medical Officer has warned that “the rise in drug-resistant diseases could result in an apocalyptic scenario, and that in twenty years’ time people will die undergoing routine operations or from what are today, simple infections, because we have run out of antibiotics”. This session will explore how we can work together to tackle the problem of anti-microbial resistance and superbugs such as MRSA and Clostridium difficile,  and showcase a couple of interesting technologies undergoing clinical trials.


Professor David Heymann CBE
Professor, LSHTM, Head, Chatham House Centre on Global Health Security and Chair,  Public Health England Advisory Board

Dr David Rhodes
Deputy Director, Public Health England


Dr Heather Fairhead
Founder and Chief Executive Officer, Phico Therapeutics

Dr April Roberts
Project Team Leader, Public Health England

Professor John Watson
England’s Deputy Chief Medical Officer

Professor Neil Woodford
Honorary Professor,  UCL and QMUL and Head of AMRHAI Reference Unit, Public Health England

12.00 – 12.45

Loose lips sink ships... but don’t use that as an excuse to avoid communicating

A panel of experts will offer their thoughts on what to say, when to say it and how to use communications to build your company brand not only in the media but also for your employees, investors and other key stakeholder


Ashley Tapp
Communications Manager, BTG and Chair,  BIA Communications Advisory Committee


Glyn Edwards MBE
Chief Executive Officer, Summit

Dr Chris Gardner
Director, Citigate Dewe

Kristen Hallam
Deputy Team Leader, European Health News, Bloomberg

Dr Navid Malik
Head of Life Sciences Research, C
enkos Securities

Public private partnerships in translational vaccinology

Learn how governments, universities and the bioscience industry can partner effectively to provide solutions to infectious diseases and bio-threat hazards.


Professor Miles Carroll
Honorary Professor in Vaccinology, University of Southampton and Deputy Director,  Public Health England


Professor Jeffrey Almond
Visiting Professor, Oxford University and V
ice President (Discovery Research and External R&D), Sanofi Pasteur, France

Dr David Griffiths-Johnson
Head of Innovation, Office for Life Sciences (BIS)


Edward Lumley Hall

12.45 – 14.00

Lunch, networking and partnering

 14.00 - 15.30

Council Room

Eleanor Davies-Colley Lecture Theatre

Vandervell Lecture Theatre


The Indian bioscience ecosystem: Opportunities and challenges

This session will describe how the key stakeholders interact in this emerging eco-system:

- Government and private sector-funded research activities, including incubators

- Emerging SMEs in the main national clusters

 - National and multi-national players active in cross-border activity


Richard Cawdell
HealthTech Lead, AcceleratorIndia


Dr Uday Phadke
Co-founder and Executive Chairman,

The top secrets to making biotech purchasing LEAN and Smart

Biotech's have never been under as much time and monetary pressures. A little time planning your processes and controls effectively can free up enormous amounts of resource to focus on business critical activities whilst also reducing costs and improving controls. Your problem could be cash flow control, project costing to attribute back to grants, clients or projects, getting the best deals, or keeping your team focused on the business’s core competence.

Session will cover:

- Issues for Biotech procurement
- Waste and LEAN Implementing
- Financial Controls and Tracking
- Getting deals in place to reduce costs
- Slick process ideas to reduce resource drain

Caroline Briggs
Managing Director, Amici Procurement

Accelerating vaccine development

Keep abreast of the latest trends and identify opportunities in clinical trials and vaccine development pertaining to seven key areas – chronic obstructive pulmonary disease, emerging infections, influenza, meningitis, pertussis, polio (post-eradication) and tuberculosis.


Professor Robert Read
Professor of Infectious Diseases, University of Southampton and Honorary Consultant, Southampton University Hospitals

Professor Andrew Gorringe
Visiting Professor,  University of Bath and Scientific Leader,  Public Health England


Professor Andrew Pollard (clinical trials)
Director, Oxford Vaccine Group and Professor of Paediatric Infection and Immunity,  University of Oxford

Dr Tom Wilkinson (COPD)
Reader, University of Southampton and Honorary Consultant,  University Hospitals Southampton

Professor Roger Hewson (emerging infections)
International Professor of VHFs and Arboviruses, Tajik Scientific Centre of Public Health and Scientific Programme Leader, Public Health England

Dr Anthony Marriott (influenza)
Project Team Leader, Public Health England

Professor Ray Borrow (meningitis)
Honorary Professor, University of Manchester and Head of Vaccine Evaluation Unit,  Public Health England

Dr Andrew Macadam (polio post-eradication)
Principal Scientist, National Institute for Biological Standards and Control

Dr Ann Rawkins (tuberculosis)
Scientific Leader, Public Health England



Life sciences opportunities in China

China has made growing the biotechnology industry one of its top priorities.  With more than one-fifth of the world’s population, it is an important market for biotech product development and manufacturing. 

Find out about the Chinese market, the opportunities and challenges that this emerging market brings for life science companies.

Flic Gabby
Managing Partner, Transcrip Partners

Dr Mary Smillie
Associate, Rouse

Mitzi Swanson
International Trade Adviser - Team Manager UK Trade & Investment


How can the bio industry sector tap into innovation and IP in academic and public bodies

This session will explore how the biosciences sector can collaborate more effectively with academic and public bodies to harness innovation and unlock IP, with best practice examples explored from both sides of the Atlantic.


Dr S.S. Vasan

Senior Business Development Manager (Research & Innovation), Public Health England


John M Clerici
Principal, Tiber Creek Partners and Partner, McKenna Long & Aldridge

Dr Susan Coller-Monarez
Branch Chief (S&T Directorate), US Department Homeland Security

Dr Iain Thomas
Head of Life Sciences, Cambridge Enterprise

Dr Penny Wilson
Innovation Platform Leader (Stratified Medicine), Technology Strategy Board


US market overview: Exploring opportunities for innovation

This session will give an overview of current bioscience scenarios in the USA and outline some key messages about doing business in the USA.  It will provide an overview of how UKTI can assist companies to approach the USA market and provide information on new UKTI initatives in the life sciences sector


Melissa Steinmetz
Business Development Manager, British Consulate-General, UK Trade & Investment

Kevin J Wilson
UKTI Sector Specialist, Healthcare and Medical Technology, UK Trade & Investment




Edward Lumley Hall

15.30 – 16.00

Refreshments, networking and partnering


Vandervell Lecture Theatre

16.00 – 16.45

Bioscience Got Talent

Hear the latest updates from TSB on the Biomedical Catalyst funding scheme and hear from five previous winners of this effective UK biotech initiative


Dr Helen Kuhlman
Lead Technologist Medicines and Healthcare,Technology Strategy Board

Companies Presenting:

  • Absynth Biologics
  • BioMoti
  • Creabilis
  • Exploristics
  • QuantuMDx

16.45 – 17.30

Just another IPO bubble or here to stay?

The US market has been going mad for biotech IPOs this year, whereas here in Europe nothing has changed.  An interesting panel discussion covering why the US has been so hot, whether it will keep going, whether we can hope for any reflected glory and whether it  amounts to a real change for biotechs, or just another bubble. Join the hot debate!


Niall McAlister
Partner, Edwards Wildman


Claire Dorrian

Senior Manager, Primary Markets, London Stock Exchange Group

Dr Sam Fazeli
Senior Analyst and European Head, Bloomberg Industries

Justin Gover
Chief Executive Officer, GW Pharmaceuticals

Peter Hoffman-Fischer
Managing Partner, Catalysis Capital Partners

Dr Harren Jhoti
President and Director, Astex Pharmaceuticals and BIA Board

17.30 – 18.00

Unleashing the promise of Biotechnology

In this session, Jim will focus on the global biotechnology landscape and how the US and UK can work together to share best practices, confront global challenges and ensure that a public policy and regulatory environment is in place to encourage entrepreneurship, investment and innovation across the biotechnology sector

James C Greenwood
President and Chief Executive, BIO

18.00 – 18.10

Summary and Close

Steve Bates
Chief Executive, BIA

18.10 – 18.40

BIA AGM (BIA members only)


Edward Lumley Hall

18.10  – 21.00

Autumn Reception